Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor.— Kulin et al1 reported the first prospective study of pregnancy outcome following maternal use of the newer serotonin selective antidepressants. They describe a total of 267 drug exposures in the first trimester and report that 49 women continued to take a selective serotonin reuptake inhibitor (SSRI) throughout the pregnancy. However, they do not describe the extent of the SSRI exposure during these pregnancies. Sertraline, paroxetine, and fluvoxamine have relatively short elimination half-lives: the half-life of fluvoxamine is 15.6 hours2 ; paroxetine, 21.0 hours3 ; and sertraline, 26 hours,4 with its less active metabolite n-desmethylsertraline having a half-life of 62 to 104 hours. Thus, it is possible that women who discontinued use of medication shortly after missing a period may have washed out the drug and reduced fetal exposure to drug to less than 6 weeks. If this is the case, it would seem premature to comment on the teratogenic risk of exposure to these newer, shorter-acting SSRIs without a larger group of women who took these medications throughout the first trimester. In addition, what conclusion can be made regarding the reproductive safety of specific compounds such as fluvoxamine, paroxetine, and sertraline when these agents were combined to generate a sample size on which the risk estimates were based?
Dr Grush is a member of the speakers bureau for Eli Lilly.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.